Mineralocorticoid receptor activation in obesity hypertension.
Obesity hypertension and metabolic syndrome have become major public health concerns. Nowadays, aldosterone is recognized as an important mediator of cardiovascular and renal damage. In the kidney, aldosterone injures glomerular visceral epithelial cells (podocytes), the final filtration barrier to plasma macromolecules, leading to proteinuria and glomerulosclerosis. Mineralocorticoid receptor (MR) antagonists effectively ameliorate proteinuria in patients or in animal models of hypertension, diabetes mellitus and chronic kidney disease (CKD), as well as in patients who experience 'aldosterone breakthrough.' Recently, clinical and experimental studies have shown that plasma aldosterone concentration is associated with obesity hypertension and metabolic syndrome. We showed that spontaneously hypertensive rats (SHR)/cp, an experimental model of obesity hypertension and metabolic syndrome, are prone to glomerular podocyte injury, proteinuria and left ventricular diastolic dysfunction, especially when the animals are fed a high-salt diet. Inappropriate activation of the aldosterone/MR system underlies the renal and cardiac injuries. Adipocyte-derived aldosterone-releasing factors (ARFs), although still unidentified, may account for aldosterone excess and the resultant target organ complication in SHR/cp. On the other hand, recent studies have shown that MR activation triggers target organ disease even in normal or low aldosterone states. We identified a small GTP (guanosine triphosphate)-binding protein, Rac1, as a novel activator of MR, and showed that this ligand-independent MR activation by Rac1 contributes to the nephropathy of several CKD models. We expect that ARFs and Rac1 can be novel therapeutic targets for metabolic syndrome and CKD. Future large-scale clinical trials are awaited to prove the efficacy of MR blockade in patients with obesity hypertension and metabolic syndrome.
Nagase
Miki
M
Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8655, Japan.
Fujita
Toshiro
T
D000450:Aldosterone / Q000502:physiology; D000818:Animals; D005075:Biological Evolution; D006801:Humans; D006973:Hypertension / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D008024:Ligands; D024821:Metabolic Syndrome / Q000378:metabolism; D000451:Mineralocorticoid Receptor Antagonists; D009765:Obesity / Q000150:complications* / Q000473:pathology / Q000503:physiopathology*; D011507:Proteinuria / Q000517:prevention & control; D051381:Rats; D018161:Receptors, Mineralocorticoid / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000502:physiology; D012982:Sodium, Dietary / Q000009:adverse effects; D013564:Sympathetic Nervous System / Q000503:physiopathology
D008024:Ligands; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D012982:Sodium, Dietary; D000450:Aldosterone